72 related articles for article (PubMed ID: 10073377)
1. The Risperidone Outcomes Study of Effectiveness (ROSE): a model for evaluating treatment strategies in typical psychiatric practice.
Mahmoud R; Engelhart L; Ollendorf D; Oster G
J Clin Psychiatry; 1999; 60 Suppl 3():42-7; discussion 48. PubMed ID: 10073377
[TBL] [Abstract][Full Text] [Related]
2. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).
Jones PB; Barnes TR; Davies L; Dunn G; Lloyd H; Hayhurst KP; Murray RM; Markwick A; Lewis SW
Arch Gen Psychiatry; 2006 Oct; 63(10):1079-87. PubMed ID: 17015810
[TBL] [Abstract][Full Text] [Related]
3. A pharmacoeconomic model of outpatient antipsychotic therapy in "revolving door" schizophrenic patients.
Glazer WM; Ereshefsky L
J Clin Psychiatry; 1996 Aug; 57(8):337-45. PubMed ID: 8752015
[TBL] [Abstract][Full Text] [Related]
4. Cost and cost-effectiveness in a randomized trial of long-acting risperidone for schizophrenia.
Barnett PG; Scott JY; Krystal JH; Rosenheck RA;
J Clin Psychiatry; 2012 May; 73(5):696-702. PubMed ID: 22697193
[TBL] [Abstract][Full Text] [Related]
5. Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectable.
Parellada E; Andrezina R; Milanova V; Glue P; Masiak M; Turner MS; Medori R; Gaebel W
J Psychopharmacol; 2005 Sep; 19(5 Suppl):5-14. PubMed ID: 16144781
[TBL] [Abstract][Full Text] [Related]
6. Challenges in the design and conduct of controlled clinical effectiveness trials in schizophrenia.
Rosenheck RA; Krystal JH; Lew R; Barnett PG; Thwin SS; Fiore L; Valley D; Huang GD; Neal C; Vertrees JE; Liang MH;
Clin Trials; 2011 Apr; 8(2):196-204. PubMed ID: 21270143
[TBL] [Abstract][Full Text] [Related]
7. Control group bias in randomized atypical antipsychotic medication trials for schizophrenia.
Woods SW; Gueorguieva RV; Baker CB; Makuch RW
Arch Gen Psychiatry; 2005 Sep; 62(9):961-70. PubMed ID: 16143728
[TBL] [Abstract][Full Text] [Related]
8. Patient-based and clinician-based support for the remission criteria in schizophrenia.
Docherty JP; Bossie CA; Lachaux B; Bouhours P; Zhu Y; Lasser R; Gharabawi GM
Int Clin Psychopharmacol; 2007 Jan; 22(1):51-5. PubMed ID: 17159460
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care.
Stargardt T; Weinbrenner S; Busse R; Juckel G; Gericke CA
J Ment Health Policy Econ; 2008 Jun; 11(2):89-97. PubMed ID: 18509216
[TBL] [Abstract][Full Text] [Related]
10. Antipsychotic medication use patterns and associated costs of care for individuals with schizophrenia.
Loosbrock DL; Zhao Z; Johnstone BM; Morris LS
J Ment Health Policy Econ; 2003 Jun; 6(2):67-75. PubMed ID: 14578539
[TBL] [Abstract][Full Text] [Related]
11. Switching to long-acting injectable risperidone is beneficial with regard to clinical outcomes, regardless of previous conventional medication in patients with schizophrenia.
Marinis TD; Saleem PT; Glue P; Arnoldussen WJ; Teijeiro R; Lex A; Latif MA; Medori R
Pharmacopsychiatry; 2007 Nov; 40(6):257-63. PubMed ID: 18030649
[TBL] [Abstract][Full Text] [Related]
12. Risperidone: clinical outcome predictors and cost-effectiveness in a naturalistic setting.
Finley PR; Sommer BR; Corbitt JL; Brunson GH; Lum BL
Psychopharmacol Bull; 1998; 34(1):75-81. PubMed ID: 9564202
[TBL] [Abstract][Full Text] [Related]
13. Sexual functioning associated with quetiapine switch vs. risperidone continuation in outpatients with schizophrenia or schizoaffective disorder: a randomized double-blind pilot trial.
Byerly MJ; Nakonezny PA; Rush AJ
Psychiatry Res; 2008 May; 159(1-2):115-20. PubMed ID: 18295343
[TBL] [Abstract][Full Text] [Related]
14. Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder.
Houthoofd SA; Morrens M; Sabbe BG
Clin Ther; 2008 Sep; 30(9):1565-89. PubMed ID: 18840365
[TBL] [Abstract][Full Text] [Related]
15. Attitudes toward antipsychotic medication: the impact of clinical variables and relationships with health professionals.
Day JC; Bentall RP; Roberts C; Randall F; Rogers A; Cattell D; Healy D; Rae P; Power C
Arch Gen Psychiatry; 2005 Jul; 62(7):717-24. PubMed ID: 15997012
[TBL] [Abstract][Full Text] [Related]
16. Formulary decisions and health economics.
Glazer WM
J Clin Psychiatry; 1998; 59 Suppl 19():23-9. PubMed ID: 9847049
[TBL] [Abstract][Full Text] [Related]
17. Insight: demographic differences and associations with one-year outcome in schizophrenia and schizoaffective disorder.
Wiffen BD; Rabinowitz J; Fleischhacker WW; David AS
Clin Schizophr Relat Psychoses; 2010 Oct; 4(3):169-75. PubMed ID: 20880827
[TBL] [Abstract][Full Text] [Related]
18. Impact of drug treatment history on comparative effectiveness research in schizophrenia.
McCombs J; Zolfaghari S; Ganapathy V
Value Health; 2011; 14(5):679-86. PubMed ID: 21839406
[TBL] [Abstract][Full Text] [Related]
19. Cost-utility analysis in schizophrenia.
Awad AG; Voruganti LP
J Clin Psychiatry; 1999; 60 Suppl 3():22-6; discussion 27-8. PubMed ID: 10073373
[TBL] [Abstract][Full Text] [Related]
20. The burden of depressive symptoms in people with schizophrenia.
Conley RR
Psychiatr Clin North Am; 2009 Dec; 32(4):853-61. PubMed ID: 19944888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
